Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Simcere Given SFDA Approval for Generic Antibiotic

publication date: May 14, 2008

Simcere Pharmaceutical Group received SFDA approval for a first-to-market generic Biapenem injection, an antibiotic that it will market under the brand name Anxin. Biapenem is a member of the carbenicillin family, and it will compete in the marketplace against brand-name drugs such as Tienam from Merck and Mepem from Sumitomo Pharmaceuticals. Carbenicillins are used in patients who have developed resistance to other antibiotics.  More details...

Stock Symbols: (NYSE: SCR) (NYSE: MRK)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here